🔎 Trials Near Me

Akèy › Limfòm selil B › Washington › Seattle

Etid klinik pou Limfòm selil B nan Seattle, WA

7 etid pou Limfòm selil B ap chèche patisipan nan sit nan ak bò kote Seattle (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Ap rekriteFaz 1
  • Swedish Cancer Institute (SCI), Seattle
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Ap rekriteFaz 1/2
  • Swedish Cancer Institute, Seattle
  • Fred Hutchinson Cancer Center, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04104776

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Ap rekriteFaz 1
  • Fred Hutch Cancer Center, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06528301

DALY II USA/ MB-CART2019.1 for DLBCL

Ap rekriteFaz 2
  • Fred Hutchinson Cancer Center, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

Ap rekriteFaz 2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Apr 23, 2026 · NCT07097363

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

Ap rekriteFaz 1
  • Providence Swedish Cancer Institute, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Nov 20, 2025 · NCT05370430

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Ap rekriteFaz 1
  • Seattle Children's Hospital, Seattle
Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770

Etid Limfòm selil B nan lòt vil

Lòt etid nan Seattle

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.